浙江江北药业有限公司

        Zhejiang Jiangbei Pharmaceutical Co., Ltd. was established in July 1993. It is a private enterprise primarily engaged in the production of active pharmaceutical ingredients (APIs), intermediates, and solid preparations. The company is recognized as a National High-Tech Enterprise, a Zhejiang Provincial Sci-Tech Enterprise, a key enterprise in Taizhou's "116" and "131" initiatives, a Taizhou High-Tech Enterprise, and a key backbone enterprise in Jiaojiang District's "522" and "2115" programs. The company oversees one trading subsidiary (Zhejiang Jiangbei Hongrui Import & Export Co., Ltd.) and two API and intermediate manufacturing companies (Zhejiang Jiangbei Nanhai Pharmaceutical Co., Ltd. and Linhai Jinqiao Chemical Co., Ltd.). 
        The company boasts a robust product portfolio, encompassing seven major categories of APIs, intermediates, and solid preparations, including cardiovascular, central nervous system, digestive tract, antiviral, anti-infective, anticoagulant, and anti-osteoporosis drugs. With self-operated import and export rights, its products are well-received domestically and exported to over 30 countries and regions, including Europe, the United States, Japan, South Korea, Brazil, India, and Southeast Asia. Currently, the company has become a significant global production and export base for cardiovascular and antiviral medications.
        Adhering to the quality policy of "Integrity, Excellence, Efficiency, and Innovation," the company upholds the principle that "Quality is by Design." It operates with integrity, focuses on customer needs, and implements its quality policy through high-quality products and a strong sense of responsibility, earning trust from society and users. Committed to meeting standards such as the U.S. FDA, EU EMA, and WHO for pharmaceutical production quality control, the company continuously enhances its pharmaceutical manufacturing processes and quality control capabilities while advancing intelligent manufacturing and automation. Products such as Simvastatin, Atorvastatin, and Levetiracetam have passed official inspections and certifications from the U.S. FDA, EU CEP, WHO, Japan, South Korea, India, and others, as well as China's new GMP inspection.
        Guided by its corporate mission of "Pursuing Excellence, Leading Health" and its corporate spirit of "Prosperity, Harmony, Progress, and Integrity," the company practices the core value of "Prioritizing Customer Interests, Fostering Cooperative Competition, and Creating Value." After more than two decades of development, it has established a strong reputation for "Excellence, Efficiency, Technological Leadership, and Superior Quality," laying a solid foundation for sustainable and healthy growth. It has become a strategic partner for many renowned domestic and international enterprises and institutions.
        Building on the present and looking toward the future, the company is continuously adjusting and optimizing its product structure while accelerating the development of its preparation industry. It aims to achieve seamless integration of intermediates, APIs, and preparations across the industrial chain, striving to become a highly competitive international pharmaceutical enterprise as soon as possible.